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Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive interruption of ventilation during sleep caused
by recurrent upper airway collapse, which leads to intermittent hypoxia. The disorder is commonly undiagnosed despite its
relationship with substantial cardiovascular morbidity and mortality. Moreover, the effects of the disorder appear to be particularly
dangerous in young subjects. In the last decade, substantial clinical evidence has identified OSA as independent risk factor for
both bradyarrhythmias and tachyarrhythmias. To date the mechanisms leading to such arrhythmias have not been completely
understood. However, recent data from animal models and new molecular analyses have increased our knowledge of the field,
which might lead to future improvement in current therapeutic strategies mainly based on continuous positive airway pressure.
This paper aims at providing readers a brief and specific revision of current knowledge about the mechanisms underlying atrial
arrhythmias in OSA and their clinical and therapeutic implications.
1. Introduction
Obstructive sleep apnea (OSA) is a relevant health problem
because of its high prevalence and concomitant severe effects
in the general population [1]. Although the disorder is mainly
present in obese men, other clinical characteristics such as
age 65 years or older, smoking, and alcohol consumption
are also common [1]. OSA is characterized by repetitive
interruption of ventilation during sleep caused by recurrent
upper airway collapse, which is associated with increasing
respiratory efforts and intermittent arterial oxygen desatu-
ration. Nocturnal arousals, loud intermittent snoring, and
increased daytime sleepiness are the main symptoms [2].
Obstructive apneas and hypopneas are considered significant
if they last for more than 10 seconds. Such episodes can be
recorded and quantified by a polysomnography study, which
remains the standard technique for the diagnosis. Currently,
international guidelines consider the diagnosis of OSA in
the presence of an apnea-hypopnea index ≥5 and persistent
respiratory effort during the episodes [2].
Cardiovascular morbidity and mortality significantly
increase in patients with untreated severe OSA [3].Moreover,
the effects of the disorder appear to be particularly dangerous
in young subjects [3, 4]. Substantial evidence supports the
association betweenOSAand cardiovascular diseases, among
which atrial arrhythmias and conduction disorders are of
particular interest [5, 6]. Abnormalities such as hypoxia or
sympathovagal imbalance are consistently present in OSA
and have been associated with atrial arrhythmias [7, 8].
Moreover, under continuous positive airway pressure (CPAP)
treatment, it has been shown the disappearance of both atrial
fibrillation (AF) and heart block in patients with severe OSA
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Figure 1: Diagram of mechanisms involved in atrial arrhythmias in patients with obstructive sleep apnea.
[8, 9]. In this workwe aim at reviewing the current knowledge
about the mechanisms underlying atrial disorders in OSA
and their implications in clinical practice, in such a way that
clinicians will be able to establish a mechanistic link from
molecular basis to animal models and clinical setting.
2. Mechanisms of Increased Risk of Atrial
Arrhythmias in OSA
Different abnormalities have been involved in the patho-
genesis of atrial arrhythmias and increased cardiovascular
risk in patients with OSA [2]. Significantly relevant is the
strong association between tachyarrhythmias, especially AF
and OSA [5]. Thus hypoxia, hypercapnia, negative intratho-
racic pressure, autonomic alterations, inflammation, increase
in intravascular volume, and left ventricular diastolic dys-
function are likely implicated in a multifactorial process
leading to functional and structural changes prompt to atrial
arrhythmias (Figure 1).
Hypoxemia significantly impairs relaxation of left and
right ventricles in healthy humans rendered hypoxemic by
breathing a variable nitrogen/oxygen mixture [10]. Similarly,
intermittent apnea-induced hypoxemia documented during
a polysomnographic study has been associated with signifi-
cant hemodynamic changes in left and right ventricular func-
tions [11, 12]. Thus, the severity of apnea-related hypoxemia
is associated with a gradual deterioration of left ventricular
filling, which may explain the presence of left ventricular
hypertrophy in patients with OSA and no history of hyper-
tension [13, 14]. Experimental evidence from animal models
has yielded some clues about the molecular mechanisms
leading to diastolic dysfunction. Thus, intermittent hypoxia
seems to increase both oxidative stress and susceptibility
of the heart to such a stress [15, 16]. In addition, myocyte
hypertrophy, apoptosis, andmultifocal infarcts have been also
associatedwith left ventricular dysfunction [17]. Interestingly,
hypoxia-induced deterioration of left ventricular filling is
significantly correlated with acute atrial changes. In a rat
model of obesity and acute OSA, increases in left ven-
tricular end diastolic pressure during obstructive apnea
correlated with significant left atrial enlargement moni-
tored by echocardiography [18]. Moreover, in the same
study Iwasaki et al. tried to elucidate the main mechanism
leading to reproducibly inducible AF in those animals. To
do so, they tested four different interventions consisting
of pharmacologic autonomic blockade, ventilatory muscle
paralysis, balloon occlusion of the inferior vena cava, and
saline injection as control. Autonomic blockade partially
decreased AF inducibility compared with control. However,
only prevention of left atrial dilatation by balloon occlusion
of the inferior vena cava was associated with significant
suppression of AF inducibility [18]. The latter suggests that
acute atrial dilatation due to apnea-related increase in left
ventricular end diastolic pressuremay prompt the atria to AF.
The results are especially relevant since acute atrial stretch
has been traditionally associated with increased vulnerability
to AF. Moreover, resumption of sinus rhythm is consistently
achieved after releasing the atrial stretch [19]. The latter has
important clinical implications in spite of the fact that mech-
anisms underlying stretch-induced AF are highly complex
and not completely understood [20]. Therefore, AF might be
terminated or prevented by correcting apnea-induced acute
hemodynamic changes in the left atrium.
In addition, hypoxia may affect atrial electrophysiology
by modifying conduction velocity and atrial refractoriness.
However, data from different animal models have yielded
divergent results, which preclude identifying conclusive
effects [21, 22]. High levels of hypercapnia may also affect
atrial electrophysiology by slowing atrial conduction and
increasing atrial refractoriness. Upon returning to normo-
capnia, refractoriness rapidly returns to baseline levels while
conduction slowing still persists. Although it is difficult
to reproduce in vivo responses to acute hypoxemia and
hypercapnia, hypercapnia-related electrophysiology changes
have been associated with AF in the sheep intact heart [23].
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Autonomic neural inputs to ganglionated plexi occurring
during apnea may initiate AF. However, the exact mech-
anisms leading to AF are extremely difficult to elucidate
because of the anatomic and physiological complexity of
the sympathetic and parasympathetic innervation of the
heart [24]. Ganglionated plexi neural activity progressively
increases before the onset of AF, which associates with
shortening of the atrial refractory period [25]. The latter
allows nonconducted premature stimuli at baseline to activate
the atrium and probably generate heterogeneity [26], which
leads to reentry and AF. Moreover, either the blockade of
both arms of the autonomic nervous system or ablation of
pericardiac fat pad containing ganglionated plexi inhibits the
occurrence of apnea-induced AF, similar to the previously
mentioned effect of releasing atrial stretch [25]. However,
acute effects of autonomic blockade may not last in the
long term, rendering AF reinducible after several weeks of
ablation-based autonomic denervation [27]. It is difficult to
determine whether autonomic inputs or atrial stretch plays
the main role in initiating and sustaining AF. Model-based
differences on the presence or absence of negative intratho-
racic pressure during apnea might be responsible for more
stretch-dependent or autonomic deregulation-dependent AF
[18, 25].
Negative intrathoracic pressure occurs during OSA due
to ineffective inspiratory efforts against the occluded upper
airway. Animal models simulating clinical OSA incorporate
negative intrathoracic pressure during tracheal occlusion,
which leads to shortening of the atrial effective refractory
period and action potential duration [18, 28]. Such electro-
physiological changes increaseAF susceptibility, which seems
to be partially mediated by vagal activation. The latter is
further supported by a high rate of AF prevention upon
atropine or vagotomy [28]. Concomitant changes in sympa-
thetic activity and atrial pressure have been also documented
[18, 29], which may increase atrial susceptibility to AF in the
presence of vagal activation. Acetylcholine-mediated AF is
facilitated by isoproterenol, which decreases the threshold of
acetylcholine concentration for AF induction and increases
AF duration [30]. Similarly, increases in left atrial pressure
and atrial dilatation decrease the conduction velocity and
increase the degree of spatial heterogeneities in conduction,
which facilitates reentry and AF [31]. Both phenomena, along
with vagal activation may generate an optimal substrate
to initiate and sustain AF. Additionally, in the presence of
hypoxia it might be expected a significant role of the ATP-
sensitive K+ current (𝐼K-ATP). However, its role seems to be
much less prominent and probably overcome by the vagal-
mediated activity [28].
Inflammation may facilitate AF in patients with atrial
substrate suitable to develop the arrhythmia. It is also possible
a direct effect of inflammatory markers on ionic channels
and signaling pathways involved in the development of
atrial fibrosis, both leading to AF [32]. Interestingly, as
inflammatory cytokines rise the risk of AF concomitantly
increases [33]. Intermittent hypoxia and hypercapnia in
animal models result in systemic inflammation and increases
in interleukin-6 (IL-6) [34]. The mechanism by which IL-6
may be produced in hypoxic conditions is the upregulation
of transcription factors NF-𝜅B (nuclear factor kappa-light-
chain-enhancer of activated B cells) and NF-IL6 (nuclear
factor for IL-6 expression) [35]. In addition, increases in IL-
6 precede increases in C-reactive protein (CRP), which is an
inflammatory mediator involved in releasing new proinflam-
matory cytokines. Patients withOSA showmarkedly elevated
monocyte and neutrophil NF-𝜅B activity [36]. Therefore, a
proinflammatory state may lead to higher susceptibility to
AF in OSA patients. Moreover, inflammation is common in
OSA patients, including elevated levels of proinflammatory
cytokines. Tumor necrosis factor-𝛼 (TNF-𝛼) and IL-6 levels
are elevated inOSA independent of obesity [37, 38]. However,
the initial trigger driving the elevation of proinflammatory
cytokines in OSA patients has not been completely eluci-
dated. Some evidence supports the role of both sides of the
autonomic nervous system and hypoxia as themain initiation
mechanisms [39].
Some of the mechanisms involved in tachyarrhythmias
have been also associated with bradyarrhythmias or asystole
in patients with severe OSA. In fact, bradycardia, significant
pauses (>3 s) and some degree of conduction block are highly
prevalent in OSA patients [40].The occurrence and degree of
bradycardia during apnea depends on the degree of hypox-
emia resulting from these apneas. Furthermore, increased
vagal efferent activity appears to cause the bradycardia, which
can be prevented by intravenous atropine [41]. Paroxysmal
parasympathetic discharges are more pronounced during
rapid eye movement (REM) sleep, which even in healthy
young subjects have been associated with marked bradycar-
dia and prolonged asystolic pauses [42]. In patients with OSA
marked bradycardia may occur particularly in REM state,
during which longer breathing pauses and greater degrees
of oxyhemoglobin desaturation occur. In addition, in OSA
there is lack of normal lung expansion during ventilation,
which prevents attenuation of parasympathetic discharges
by vagolytic properties of normal lung expansion [43]. The
influence of parasympathetic tone is further supported by
clinical electrophysiological studies revealing no evidence for
advanced sinus node disease or atrioventricular conduction
systemdysfunction, which suggest that prolonged ventricular
asystole during OSA is not due to fixed or anatomic disease
of the sinus node or the atrioventricular conduction system
[44]. Animal models aimed at studying AF in OSA have also
shown slowing of the heart rate concurrent with increased
blood pressure after the initiation of apnea [25, 28]. The
effects are compatible with simultaneous increases in cardiac
parasympathetic and vasoconstricting sympathetic tone, sim-
ilar to the diving reflex seen in mammals, during which the
body responds to apnea by increasing sympathetic tone to the
peripheral vasculature and parasympathetic tone to the heart
[45].
3. Clinical Significance of Atrial Arrhythmias
in OSA Patients
In the early 80’s a potential relationship between OSA and
AF emerged from an observational, uncontrolled study by
Guilleminault et al., in which the use of 24-hour holter
4 Pulmonary Medicine
electrocardiography identified a prevalence of nocturnal
paroxysms of AF of ≈3% in OSA patients compared with the
general population prevalence of 0.4 to 1% [46]. The same
study reported sinus arrest lasting for more than 2.5 seconds
and second-degree atrioventricular conduction block in 10%
and 7% of OSA patients, respectively.
In a large cohort of 3542 patients who underwent their
first diagnostic polysomnogram study and further average
follows up of 4.7 years, obesity and OSA were independent
risk factors for incident AF in individuals <65 years of
age [47]. Moreover, the magnitude of nocturnal oxygen
desaturation is consistently present in several studies as
independently predictive of AF [47–49]. The latter provides
further support to hypoxemia-related pathophysiological
changes in AF onset.
OSA and AF have been linked in different clinical
settings. Thus, an apnea-hypopnea index (AHI) ≥5 was
associated with significant higher risk of postcoronary artery
bypass surgery AF compared with lower values of AHI [49].
Recurrence of AF was also associated with untreated OSA
in a prospective cohort of patients who underwent electrical
cardioversion and one-year follow up [48]. More recently,
data from several observational studies have supported the
assertion that OSA patients diagnosed using polysomnog-
raphy have significantly greater AF recurrence rates after
pulmonary vein isolation compared with controls [50]. Such
a higher risk of recurrences might be explained by significant
differences in atrial remodeling compared with patients who
underwent catheter ablation of AF and an AHI ≤15. In fact,
OSA is associated with significant larger atrial enlargement,
lower atrial voltage, and more site-specific and widespread
conduction abnormalities [51].
OSA is also an independent risk factor for stroke. There-
fore it would be particularly relevant to determine a potential
increased risk of stroke in AF patients with OSA. Although
such data is not available to date, some clues indicate that
OSA may have a role in stroke risk stratification scores in
patients with AF. Thus, OSA is strongly associated with AF
and most of the relative risks included in current stroke risk
stratification scores are very similar between AF and OSA
patients [52, 53]. In addition, OSA is associated with other
risk factors in AF such as hypertension and diabetes mellitus
[54].
Bradyarrhythmia and sinus pauses are commonly
described in patients with OSA. However, there is a
huge variability between trials, which show incidences
ranging from 5% to 50% [6, 40, 46]. Even no differences
in conduction delay disturbances between severe sleep-
disordered breathing and controls have been reported using
retrospective ECGdata recorded during the sleep period [55].
Noncomparable study designs, methods, and populations
may explain such differences. The large intraindividual
variability reported by Simantirakis et al. in a cohort of
patients with moderate to severe OSA who underwent
continuous monitoring by implantable loop recorder [40],
demonstrates the incapability of 24-hour and 48-hour
holter monitoring to accurately determine the incidence
of atrial arrhythmias. Therefore, assuming that continuous
ECG monitoring is the most reliable tool to determine the
incidence of cardiac arrhythmias, approximately half of
OSA patients evidence severe cardiac rhythm disturbances
[40]. Moreover, the frequency and severity of apnea-related
nocturnal bradyarrhythmias correlate with body mass index,
AHI, and desaturation level during the sleep study [6, 40, 56].
Other ECG parameters such as QT interval are affected
by the severity of the sleep apnea. Thus, QT corrected
interval is increased in patients with moderate to severe OSA
[57]. Moreover, QT corrected interval dispersion, defined
as the difference between the maximum and minimum
QT intervals, shows a strong positive correlation with the
AHI [58]. Nocturnal prolonged cycle lengths can facilitate
the occurrence of early afterdepolarizations and ventricular
arrhythmias including torsades de pointes. Both increased
QT interval and QT corrected interval dispersion are of
interest inOSA individuals particularly sensitive to nocturnal
heart rate pauses and QT prolongation such as patients
treated with class III antiarrhythmic agents or with diuretics,
along with subsets of patients with the long QT syndrome.
Although several factors are involved, serious and potentially
fatal arrhythmias may occur during sleep in patients with
OSA, which is especially relevant between 10 p.m. and 6 a.m
[59] (see Table 1 with supplementary information about risk
of atrial arrhythmias in OSA).
4. Clinical Implications of Appropriate
Treatment in OSA Patients with Atrial
Arrhythmias
From the foregoing, we have discussed and provided sub-
stantial scientific support about the mechanisms and clinical
impact of atrial arrhythmias in OSA patients. However, to
date it is still difficult to determine the exact role of OSA
treatment in preventing atrial arrhythmias. Current clinical
consensus recommends that OSA should be treated with
continuous positive airway pressure (CPAP) for ventilatory
support as well as a tool for secondary prevention of cardiac
problems [60]. It is not clear either whether other modes of
ventilatory support such as bilevel pressure support (BPAP)
offer any advantages over the conventional CPAP. Nowadays,
BPAP should be reserved for patients with ventilatory failure
[60].
Direct evidence of long-lasting apneic events (≈48 s)
preceding AF onset has been rarely reported [9]. However,
it suggests a causal association between OSA and AF. Fur-
thermore, a period without apneas leads to spontaneous
resumption to sinus rhythm. Appropriate CPAP therapy
in OSA patients with AF who underwent electrical car-
dioversion significantly reduced AF recurrences after 12-
month followup. AF recurred in only 42% of OSA patients
effectively treated with CPAP, compared to 82% in untreated
patients. Interestingly, recurrence rates were also significantly
lower than in randomly selected controls without previous
history of polysomnography, which suggests the presence
of undiagnosed OSA among controls [48]. Recently, a large
series by Abe et al. has shown that treatment with CPAP
therapy significantly prevents OSA-associated paroxysmal
AF in patients with moderate to severe nocturnal apneas
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Table 1: Risk of atrial arrhythmias in obstructive sleep apnea.
Author, year Design Study population Diagnosticmethod
𝑁 of
patients Cardiac monitoring Results
Guilleminault et
al., 1983 [46] Uncontrolled Severe OSA PSG 400 24 h holter ECG
Nocturnal paroxysms of
AF in ≈3% of OSA
patients
Sinus arrest and AV block
in 10% and 7% of OSA
patients
Gami et al., 2007
[47]
Observational
retrospective
Adults underwent
a 1st PSG study.
No AF at baseline
PSG 3542
N/A. Medical
index diagnostic codes
for AF
Obesity and OSA were
independent risk factors
for incident AF
Mooe et al., 1996
[49]
Observational
prospective
Patients
underwent
CABG surgery
PSG 121 Prospective monitoringuntil discharge
AHI ≥ 5 was associated
with significant higher
risk of postsurgical AF
Ng et al., 2011 [50]
Meta-analysis
(observational
studies)
Patients
underwent PVI
PSG/Berlin
questionnaire 3995
24/48 h holter ECG
Event monitor/recorder
Telephone follow-up
ECG
OSA led to greater AF
recurrence rates after PVI
Simantirakis et
al., 2004 [40]
Observational
prospective
Moderate-severe
OSA PSG 23
Implantable loop
recorder
Cardiac pauses >3 s and
bradycardic
episodes <40 bpm in 47%
of patients
Becker, 1998 [6] Observationalprospective Unselected OSA PSG 239 24 h holter ECG
2nd- and 3rd-degree AV
block and/or sinus arrest
in ≈7.5% of OSA patients
Hoffstein and
Mateika, 1994
[56]
Observational
prospective
Patients
underwent PSG
study
PSG 458 Single lead ECGduring PSG
58% prevalence of
arrhythmias in OSA
patients
AF: atrial fibrillation; AHI: apnea/hypopnea index; AV block: atrioventricular block; CABG: coronary artery bypass graft; OSA: obstructive sleep apnea; PSG:
polysomnography; PVI: pulmonary vein isolation.
[61]. Similar to previous series and considering the above-
mentioned limitation of limited electrocardiographic record-
ing period during polysomnography [46], CPAP therapy
significantly eliminates sinus bradycardia and sinus pauses.
Only a trend to significant differences before and after CPAP
therapy was also present in episodes of second-and third-
degree atrioventricular block [61].The lattermay be explained
by the limitedmonitoring period and very low rate of second-
and third- degree atrioventricular block, which precludes
reaching statistical significance.
Untreated OSA patients have higher recurrence rates
after catheter ablation of AF. Such higher recurrence rates
are also associated with the presence of more prevalent
nonpulmonary veins triggers [62]. More recently Naruse et
al. have suggested that an AHI of more than 10 has predictive
value of AF recurrences after AF ablation. Moreover, CPAP
therapy reduces the risk of recurrent AF after pulmonary vein
isolation in patients with an AHI >5 [63]. AF recurrences
were also reduced in the followup of patientswith atrial flutter
who underwent radiofrequency ablation of cavotricuspid
isthmus (CTI) and proper CPAP therapy [64]. However,
CPAPwas only protective fromAF recurrences when AF was
not present prior to CTI ablation.
The exact mechanisms for preventing AF recurrences by
CPAP therapy are not understood. Beyond preventing upper
airway obstruction, correcting hypoxemia, and decreasing
the AHI, CPAP therapy seems to attenuate oxidative stress
and systemic inflammation [65], which has been associated
with both incident AF and AF recurrences after catheter
ablation [66, 67].
The effects of CPAP therapy have been also studied in
patients with OSA and bradyarrhythmia. Cornerstone series
by Guilleminault et al. in the early 80’s initially suggested
that preventing upper airway obstruction by tracheostomy
completely abolished conduction disturbances at 6 months
of followup [46]. Case reports have also documented com-
plete reversion of second-degree atrioventricular block after
initiation of CPAP treatment [68]. During polysomnography
the vast majority of the apnea-associated bradyarrhythmias
occur during rapid eye movement sleep and significant
desaturation of at least 4%. Both CPAP and BPAP drastically
decrease the AHI and bradyarrhythmias [69]. More accurate
followup using implantable loop recorders shows that the ini-
tiation of CPAP therapy tends to reduce the total number of
the recorded episodes in the short termwhile in the long term
bradycardia episodes are completely abolished [40]. CPAP
therapy also has the capability to decrease the QT corrected
interval dispersion present at baseline in patients with mod-
erate to severeOSA [58].The lattermight have implications in
preventing bradycardia-related early afterdepolarizations and
ventricular arrhythmias leading to nocturnal sudden death
(see Table 2 with supplementary information about effects
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Table 2: Effects of CPAP therapy on atrial arrhythmia outcomes in OSA patients.
Author, year Design Study population Diagnosticmethod
𝑁 of
patients
Cardiac
monitoring Results
Kanagala et al.,
2003 [48]
Observational
prospective
Patients
underwent
AF/AFL DC
shock
PSG 121
Hospital records
Phone interviews
ECG
Medical visits
AF recurrences in 42% of
OSA treated with CPAP
AF recurrences in 82% of
untreated patients
Abe et al., 2010
[61]
Nonrandomized
prospective
Adults underwent
PSG study PSG 1456
ECG monitoring
during PSG
CPAP prevented AF, sinus
bradycardia/pauses in
patients with moderate to
severe OSA
Naruse et al.,
2013 [63]
Nonrandomized
prospective
Patients
underwent
PVI isolation
PSG 153
12-lead ECG
24 h holter ECG
Portable ECG
monitoring
Untreated OSA showed
higher recurrence of AF
after ablation
Koehler et al.,
1998 [69]
Nonrandomized
prospective
OSA patients
with
bradyarrhythmia
PSG 16 ECG monitoringduring PSG
CPAP and BPAP
drastically decreased
bradyarrhythmias
Simantirakis et
al., 2004 [40]
Observational
prospective
Moderate-severe
OSA PSG 23
Implantable loop
recorder
Long-term CPAP therapy
completely abolished
bradycardia episodes
AF: atrial fibrillation; AFL: atrial flutter; CPAP: continuous positive airway pressure; OSA: obstructive sleep apnea; PSG: polysomnography; PVI: pulmonary
vein isolation.
of CPAP therapy on atrial arrhythmia outcomes in OSA
patients).
However, one important limitation ofCPAP therapy is the
poor long-term acceptance of treatment. Approximately 40%
of patients are no longer complaint with the treatment after
3 years [70]. However, it seems that patients with the most
severe sleep apnea are more likely to be complaint. The most
common reason for discontinuing is intolerance of the mask
[71]. Moreover, mask leak is a major independent predictor
of CPAP compliance; therefore reducing mask leak predicts
good compliance with CPAP therapy [72].
Finally, based on the benefits of CPAP therapy and such
a frequent undiagnosed disorder in the general population,
screening for OSA in patients with both AF and atrial
flutter appears to be a reasonable clinical strategy if either a
clinical or catheter-based rhythm control strategy is pursued.
It seems also reasonable to identify patients with apnea-
related bradyarrhythmias, since appropriate treatment may
completely abolish its presence.
5. Conclusions and Future Directions
Atrial arrhythmias are highly prevalent in patients with
moderate to severe obstructive sleep apnea, which has been
identified as independent risk factor for both bradyarrhyth-
mias and tachyarrhythmias. Hypoxia, hypercapnia, auto-
nomic dysfunction, acute atrial stretch, negative intrathoracic
pressure, and inflammation are some of the mechanisms
leading to arrhythmia. However, complete understanding of
such mechanisms is still ongoing and further research based
on animalmodels is needed. CPAP therapy has demonstrated
significant improvement in preventing and even abolishing
atrial arrhythmias. However, it is necessary to improve and
develop alternatives to conventional CPAP, which help to
prevent current high rates of treatment discontinuation in the
long-term.
References
[1] T. Young,M. Palta, J. Dempsey, J. Skatrud, S.Weber, and S. Badr,
“The occurrence of sleep-disordered breathing among middle-
aged adults,”The New England Journal of Medicine, vol. 328, no.
17, pp. 1230–1235, 1993.
[2] G. Parati, C. Lombardi, J. Hedner et al. et al., “Position paper on
the management of patients with obstructive sleep apnea and
hypertension: joint recommendations by the European Society
of Hypertension, by the European Respiratory Society and by
the members of European COST (COoperation in Scientific
and Technological research) ACTION B26 on obstructive sleep
apnea,” Journal ofHypertension, vol. 30, no. 4, pp. 633–646, 2012.
[3] J.M.Marin, S. J. Carrizo, E. Vicente, andA.G.N. Agusti, “Long-
term cardiovascular outcomes in men with obstructive sleep
apnoea-hypopnoea with or without treatment with continuous
positive airway pressure: an observational study,” The Lancet,
vol. 365, no. 9464, pp. 1046–1053, 2005.
[4] P. Lavie, L. Lavie, and P. Herer, “All-cause mortality in males
with sleep apnoea syndrome: declining mortality rates with
age,” European Respiratory Journal, vol. 25, no. 3, pp. 514–520,
2005.
[5] A. S. Gami, G. Pressman, S. M. Caples et al., “Association of
atrial fibrillation and obstructive sleep apnea,” Circulation, vol.
110, no. 4, pp. 364–367, 2004.
[6] H. F. Becker, “Heart block in patients with sleep apnoea,”
Thorax, vol. 53, no. 3, pp. S29–S32, 1998.
[7] R. Tkacova, F. Rankin, F. S. Fitzgerald, J. S. Floras, and T.
D. Bradley, “Effects of continuous positive airway pressure on
obstructive sleep apnea and left ventricular afterload in patients
with heart failure,” Circulation, vol. 98, no. 21, pp. 2269–2275,
1998.
Pulmonary Medicine 7
[8] F. Roche, A. N. T. Xuong, I. Court-Fortune et al., “Relation-
ship among the severity of sleep apnea syndrome, cardiac
arrhythmias, and autonomic imbalance,” Pacing and Clinical
Electrophysiology, vol. 26, no. 3, pp. 669–677, 2003.
[9] R. Schulz, H. J. Eisele, and W. Seeger, “Nocturnal atrial fibrilla-
tion in a patient with obstructive sleep apnoea,”Thorax, vol. 60,
no. 2, article 174, 2005.
[10] R. I. Cargill, D. G. Kiely, and B. J. Lipworth, “Adverse effects of
hypoxaemia on diastolic filling in humans,”Clinical Science, vol.
89, no. 2, pp. 165–169, 1995.
[11] S. Q. Yang, L. L. Han, X. L. Dong et al., “Mal-effects of
obstructive sleep apnea on the heart,” Sleep Breath, vol. 16, no.
3, pp. 717–722, 2012.
[12] H. Kraiczi, K. Caidahl, A. Samuelsson, Y. Peker, and J. Hedner,
“Impairment of vascular endothelial function and left ven-
tricular filling: association with the severity of apnea-induced
hypoxemia during sleep,” Chest, vol. 119, no. 4, pp. 1085–1091,
2001.
[13] J. Hedner, H. Ejnell, and K. Caidahl, “Left ventricular hypertro-
phy independent of hypertension in patients with obstructive
sleep apnoea,” Journal of Hypertension, vol. 8, no. 10, pp. 941–
946, 1990.
[14] M. A. Arias, F. Garc´ıa-Rı´o, A. Alonso-Ferna´ndez, O. Mediano,
I.Mart´ınez, and J. Villamor, “Obstructive sleep apnea syndrome
affects left ventricular diastolic function: effects of nasal contin-
uous positive airway pressure in men,” Circulation, vol. 112, no.
3, pp. 375–383, 2005.
[15] A. M. Park and Y. J. Suzuki, “Effects of intermittent hypoxia on
oxidative stress-induced myocardial damage in mice,” Journal
of Applied Physiology, vol. 102, no. 5, pp. 1806–1814, 2007.
[16] T. Hayashi, C. Yamashita, C. Matsumoto et al., “Role of
gp91phox-containing NADPH oxidase in left ventricular
remodeling induced by intermittent hypoxic stress,” American
Journal of Physiology, vol. 294, no. 5, pp. H2197–H2203, 2008.
[17] R. Farre´, J. M. Montserrat, and D. Navajas, “Morbidity due to
obstructive sleep apnea: insights from animal models,” Current
Opinion in Pulmonary Medicine, vol. 14, no. 6, pp. 530–536,
2008.
[18] Y. K. Iwasaki, Y. Shi, B. Benito et al., “Determinants of atrial
fibrillation in an animal model of obesity and acute obstructive
sleep apnea,” Heart Rhythm, vol. 9, no. 9, pp. 1409.e1–1416.e1,
2012.
[19] F. Ravelli and M. Allessie, “Effects of atrial dilatation on
refractory period and vulnerability to atrial fibrillation in the
isolated Langendorff-perfused rabbit heart,”Circulation, vol. 96,
no. 5, pp. 1686–1695, 1997.
[20] D. Filgueiras-Rama, R. P. Martins, S. Mironov et al. et
al., “Chloroquine terminates stretch-induced atrial fibrillation
more effectively than flecainide in the sheep heart,” Circulation,
vol. 5, no. 3, pp. 561–570, 2012.
[21] P. C. Krause, H. Inoue, and D. P. Zipes, “Electrophysiologic
alterations produced by hypoxia in the canine heart,” American
Heart Journal, vol. 117, no. 3, pp. 550–561, 1989.
[22] W. J. E. P. Lammers, C. Kirchhof, F. I. M. Bonke, and M. A.
Allessie, “Vulnerability of rabbit atrium to reentry by hypoxia.
Role of inhomogeneity in conduction and wavelength,” Ameri-
can Journal of Physiology, vol. 262, no. 1, pp. H47–H55, 1992.
[23] I. H. Stevenson, K. C. Roberts-Thomson, P. M. Kistler et al.,
“Atrial electrophysiology is altered by acute hypercapnia but not
hypoxemia: implications for promotion of atrial fibrillation in
pulmonary disease and sleep apnea,” Heart Rhythm, vol. 7, no.
9, pp. 1263–1270, 2010.
[24] A. Puodziukynas, T. Kazakevicius, R. Vaitkevicius et al. et al.,
“Radiofrequency catheter ablation of pulmonary vein roots
results in axonal degeneration of distal epicardial nerves,”
Autonomic Neuroscience, vol. 167, pp. 61–65, 2012.
[25] M. Ghias, B. J. Scherlag, Z. Lu et al., “The role of ganglionated
plexi in Apnea-related atrial fibrillation,” Journal of the Ameri-
can College of Cardiology, vol. 54, no. 22, pp. 2075–2083, 2009.
[26] G. K. Moe, W. C. Rheinboldt, and J. A. Abildskov, “A computer
model of atrial fibrillation,” American Heart Journal, vol. 67, no.
2, pp. 200–220, 1964.
[27] S. Oh, Y. Zhang, S. Bibevski, N. F. Marrouche, A. Natale,
and T. N. Mazgalev, “Vagal denervation and atrial fibrillation
inducibility: epicardial fat pad ablation does not have long-term
effects,” Heart Rhythm, vol. 3, no. 6, pp. 701–708, 2006.
[28] D. Linz, U. Schotten, H. R. Neuberger, M. Bo¨hm, and K.
Wirth, “Negative tracheal pressure during obstructive respi-
ratory events promotes atrial fibrillation by vagal activation,”
Heart Rhythm, no. 9, pp. 1436–1443, 2011.
[29] D. Linz, F. Mahfoud, U. Schotten et al., “Renal sympathetic
denervation suppresses postapneic blood pressure rises and
atrial fibrillation in a model for sleep apnea,” Hypertension, vol.
60, no. 1, pp. 172–178, 2012.
[30] O. F. Sharifov, V. V. Fedorov, G.G. Beloshapko, A. V.Glukhov, A.
V. Yushmanova, and L. V. Rosenshtraukh, “Roles of adrenergic
and cholinergic stimulation in spontaneous atrial fibrillation in
dogs,” Journal of the American College of Cardiology, vol. 43, no.
3, pp. 483–490, 2004.
[31] S. C. M. Eijsbouts, R. P. M. Houben, Y. Blaauw, U. Schotten,
and M. A. Allessie, “Synergistic action of atrial dilation and
sodiumchannel blockade on conduction in rabbit atria,” Journal
of Cardiovascular Electrophysiology, vol. 15, no. 12, pp. 1453–1461,
2004.
[32] R. Ramos-Mondrago´n, A. V. Vega, and G. Avila, “Long-term
modulation of Na+ and K+ channels by TGF-𝛽1 in neonatal
rat cardiac myocytes,” Pflugers Archiv European Journal of
Physiology, vol. 461, no. 2, pp. 235–247, 2011.
[33] B. Richter, M. Gwechenberger, A. Socas et al., “Markers of
oxidative stress after ablation of atrial fibrillation are associated
with inflammation, delivered radiofrequency energy and early
recurrence of atrial fibrillation,” Clinical Research in Cardiology,
vol. 101, no. 3, pp. 217–225, 2012.
[34] C. S. Tam, M. Wong, K. Tam, L. Aouad, and K. A. Waters, “The
effect of acute intermittent hypercapnic hypoxia treatment on
IL-6, TNF-𝛼, and CRP levels in piglets,” Sleep, vol. 30, no. 6, pp.
723–727, 2007.
[35] H.Matsui, Y. Ihara, Y. Fujio et al., “Induction of interleukin (IL)-
6 by hypoxia is mediated by nuclear factor (NF)-𝜅B andNF-IL6
in cardiac myocytes,” Cardiovascular Research, vol. 42, no. 1, pp.
104–112, 1999.
[36] A. K. Htoo, H. Greenberg, S. Tongia et al., “Activation of nuclear
factor kB in obstructive sleep apnea: a pathway leading to
systemic inflammation,” Sleep and Breathing, vol. 10, no. 1, pp.
43–50, 2006.
[37] M. A. Arias, F. Garc´ıa-Rı´o, A. Alonso-Ferna´ndez et al., “CPAP
decreases plasma levels of soluble tumour necrosis factor-𝛼
receptor 1 in obstructive sleep apnoea,” European Respiratory
Journal, vol. 32, no. 4, pp. 1009–1015, 2008.
[38] A. N. Vgontzas, D. A. Papanicolaou, E. O. Bixler, A. Kales,
K. Tyson, and G. P. Chrousos, “Elevation of plasma cytokines
in disorders of excessive daytime sleepiness: role of sleep
disturbance and obesity,” Journal of Clinical Endocrinology and
Metabolism, vol. 82, no. 5, pp. 1313–1316, 1997.
8 Pulmonary Medicine
[39] P. J. Mills and J. E. Dimsdale, “Sleep apnea: a model for studying
cytokines, sleep, and sleep disruption,” Brain, Behavior, and
Immunity, vol. 18, no. 4, pp. 298–303, 2004.
[40] E. N. Simantirakis, S. I. Schiza, M. E. Marketou et al., “Severe
bradyarrhythmias in patients with sleep apnoea: the effect of
continuous positive airway pressure treatment: a long-term
evaluation using an insertable loop recorder,” European Heart
Journal, vol. 25, no. 12, pp. 1070–1076, 2004.
[41] C. Zwillich, T. Devlin, and D. White, “Bradycardia during
sleep apnea. Characteristics andmechanism,” Journal of Clinical
Investigation, vol. 69, no. 6, pp. 1286–1292, 1982.
[42] C.Guilleminault, P. Pool, J.Motta, andA.M.Gillis, “Sinus arrest
during REM sleep in young adults,”TheNew England Journal of
Medicine, vol. 311, no. 16, pp. 1006–1010, 1984.
[43] V. K. Somers, M. E. Dyken, and J. L. Skinner, “Autonomic and
hemodynamic responses and interactions during the Mueller
maneuver in humans,” Journal of the Autonomic Nervous Sys-
tem, vol. 44, no. 2-3, pp. 253–259, 1993.
[44] W. Grimm, J. Hoffmann, V. Menz et al., “Electrophysiologic
evaluation of sinus node function and atrioventricular con-
duction in patients with prolonged ventricular asystole during
obstructive sleep apnea,” American Journal of Cardiology, vol.
77, no. 15, pp. 1310–1314, 1996.
[45] J. Fagius andG. Sundlof, “Thediving response inman: effects on
sympathetic activity in muscle and skin nerve fascicles,” Journal
of Physiology, vol. 377, pp. 429–443, 1986.
[46] C. Guilleminault, S. J. Connolly, and R. A. Winkle, “Cardiac
arrhythmia and conduction disturbances during sleep in 400
patients with sleep apnea syndrome,” American Journal of
Cardiology, vol. 52, no. 5, pp. 490–494, 1983.
[47] A. S. Gami, D. O. Hodge, R. M. Herges et al., “Obstructive sleep
apnea, obesity, and the risk of incident atrial fibrillation,” Journal
of the American College of Cardiology, vol. 49, no. 5, pp. 565–571,
2007.
[48] R. Kanagala, N. S. Murali, P. A. Friedman et al., “Obstructive
sleep apnea and the recurrence of atrial fibrillation,”Circulation,
vol. 107, no. 20, pp. 2589–2594, 2003.
[49] T. Mooe, S. Gullsby, T. Rabben, and P. Eriksson, “Sleep-
disordered breathing: a novel predictor of atrial fibrillation after
coronary artery bypass surgery,”Coronary Artery Disease, vol. 7,
no. 6, pp. 475–478, 1996.
[50] C. Y. Ng, T. Liu, M. Shehata, S. Stevens, S. S. Chugh, and X.
Wang, “Meta-analysis of obstructive sleep apnea as predictor of
atrial fibrillation recurrence after catheter ablation,” American
Journal of Cardiology, vol. 108, no. 1, pp. 47–51, 2011.
[51] H. Dimitri, M. Ng, A. G. Brooks et al. et al., “Atrial remodeling
in obstructive sleep apnea: implications for atrial fibrillation,”
Heart Rhythm, vol. 9, no. 3, pp. 321–327, 2012.
[52] R. G. Hart, L. A. Pearce, G. W. Albers et al., “Independent pre-
dictors of stroke in patients with atrial fibrillation: a systematic
review,” Neurology, vol. 69, no. 6, pp. 546–554, 2007.
[53] F. Valham, T.Mooe, T. Rabben,H. Stenlund, U.Wiklund, andK.
A. Franklin, “Increased risk of stroke in patients with coronary
artery disease and sleep apnea: a 10-year follow-up,”Circulation,
vol. 118, no. 9, pp. 955–960, 2008.
[54] W. T. McNicholas and M. R. Bonsignore, “Sleep apnoea as an
independent risk for cardiovascular disease: current evidence,
basic mechanisms and research priorities,” European Respira-
tory Journal, vol. 29, no. 1, pp. 156–178, 2007.
[55] R. Mehra, E. J. Benjamin, E. Shahar et al., “Association of
nocturnal arrhythmias with sleep-disordered breathing: the
sleep heart health study,” American Journal of Respiratory and
Critical Care Medicine, vol. 173, no. 8, pp. 910–916, 2006.
[56] V. Hoffstein and S.Mateika, “Cardiac arrhythmias, snoring, and
sleep apnea,” Chest, vol. 106, no. 2, pp. 466–471, 1994.
[57] D. Cicek, H. Lakadamyali, S. Gokay, I. Sapmaz, and H. Mud-
errisoglu, “Effect of obstructive sleep apnea on heart rate,
heart rate recovery and QTc and P-wave dispersion in newly
diagnosed untreated patients,” American Journal of the Medical
Sciences, vol. 344, no. 3, pp. 180–185, 2012.
[58] D. Dursunoglu and N. Dursunoglu, “Effect of CPAP on QT
interval dispersion in obstructive sleep apnea patients without
hypertension,” Sleep Medicine, vol. 8, no. 5, pp. 478–483, 2007.
[59] A. S. Gami, D. E. Howard, E. J. Olson, and V. K. Somers, “Day-
night pattern of sudden death in obstructive sleep apnea,” The
New England Journal of Medicine, vol. 352, no. 12, pp. 1206–1214,
2005.
[60] J. Fleetham, N. Ayas, D. Bradley et al., “Canadian Thoracic
Society 2011 guideline update: diagnosis and treatment of sleep
disordered breathing,”Canadian Respiratory Journal, vol. 18, no.
1, pp. 25–47, 2011.
[61] H. Abe,M. Takahashi, H. Yaegashi et al., “Efficacy of continuous
positive airway pressure on arrhythmias in obstructive sleep
apnea patients,”Heart and Vessels, vol. 25, no. 1, pp. 63–69, 2010.
[62] D. Patel, P. Mohanty, L. Di Biase et al., “Safety and efficacy of
pulmonary vein antral isolation in patients with obstructive
sleep apnea: the impact of continuous positive airway pressure,”
Circulation, vol. 3, no. 5, pp. 445–451, 2010.
[63] Y. Naruse, H. Tada, M. Satoh et al. et al., “Concomitant obstruc-
tive sleep apnea increases the recurrence of atrial fibrillation
following radiofrequency catheter ablation of atrial fibrillation:
clinical impact of continuous positive airway pressure therapy,”
Heart Rhythm, vol. 10, no. 3, pp. 331–337, 2013.
[64] V. Bazan, N. Grau, E. Valles et al. et al., “Obstructive sleep apnea
in patients with typical atrial flutter: prevalence and impact on
arrhythmia control outcome,” Chest. In press.
[65] M. Murri, J. Alca´zar-Ramı´rez, L. Garrido-Sa´nchez et al.,
“Oxidative stress and metabolic changes after continuous posi-
tive airway pressure treatment according to previous metabolic
disorders in sleep apnea-hypopnea syndrome patients,” Trans-
lational Research, vol. 154, no. 3, pp. 111–121, 2009.
[66] K. Ishida, F. Kimura, M. Imamaki et al., “Relation of inflam-
matory cytokines to atrial fibrillation after off-pump coronary
artery bypass grafting,” European Journal of Cardio-Thoracic
Surgery, vol. 29, no. 4, pp. 501–505, 2006.
[67] S. Deftereos, G. Giannopoulos, C. Kossyvakis et al. et al.,
“Colchicine for prevention of early atrial fibrillation recurrence
after pulmonary vein isolation: a randomized controlled study,”
Journal of the American College of Cardiology, vol. 60, no. 18, pp.
1790–1796, 2012.
[68] R. Dziewas, T. Imai, R. Dittrich et al., “Night-time brad-
yarrhythmia in a patient with mild obstructive sleep apnea
syndrome is reversed with CPAP treatment,” Journal of Clinical
Sleep Medicine, vol. 2, no. 4, pp. 454–457, 2006.
[69] U. Koehler, E. Fus, W. Grimm et al., “Heart block in patients
with obstructive sleep apnoea: pathogenetic factors and effects
of treatment,” European Respiratory Journal, vol. 11, no. 2, pp.
434–439, 1998.
[70] A. Abdelghani, S. Slama, A. Hayouni et al., “Acceptance and
long-term compliance to continuous positive airway pressure
in obstructive sleep apnea. A prospective study on 72 patients
treated between 2004 and 2007,”Revue de Pneumologie Clinique,
vol. 65, no. 3, pp. 147–152, 2009.
Pulmonary Medicine 9
[71] I. Rolfe, L. G. Olson, and N. A. Saunders, “Long-term accep-
tance of continuous positive airway pressure in obstructive
sleep apnea,” American Review of Respiratory Disease, vol. 144,
no. 5, pp. 1130–1133, 1991.
[72] Z. Sopkova, Z. Dorkova, and R. Tkacova, “Predictors of com-
pliance with continuous positive airway pressure treatment in
patients with obstructive sleep apnea andmetabolic syndrome,”
Wiener Klinische Wochenschrift, vol. 121, no. 11-12, pp. 398–404,
2009.
